All studies
Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer's Disease
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Abbvie Deutschland GmbH & Co. KG
Enrolment target
98
Start
28 Jul 2023
What is this study about?
The primary efficacy endpoint for Stage B is change from Baseline in brain amyloid plaque deposition (amyloid centiloid value) at Week 24 as measured by amyloid PET scan.
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (3)
- —Portugal
- —Italy
- —Spain
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.